Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) announced that its self-developed, first-in-class, new-concept bispecific ADC (Antibody-Drug Conjugate) iza-bren for injection has been included in the Priority Review list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. According to publicly available information, iza-bren is also the first EGFR×HER3 bispecific ADC globally to be included in a Priority Review program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments